This disclosure relates to processes to form arylcyclopropyl carboxylic acids useful in forming molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda.

This disclosure relates to processes to form arylcyclopropyl carboxylic acids useful in forming molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda.

Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

The present invention belongs to the technical field of fine chemicals and relates to a new crystalline form of tefluthrin, a preparation method therefor and the use thereof. The preparation method specifically comprises: taking an amorphous tefluthrin or a solid tefluthrin other than the tefluthrin as described in the present invention as a raw material, firstly preparing the raw material into an amorphous substance at room temperature, and then allowing the amorphous substance to cool to 5° C. to −24° C. to obtain a white or light yellow solid, i.e., a new crystalline form of tefluthrin.

The present invention belongs to the technical field of fine chemicals and relates to a new crystalline form of tefluthrin, a preparation method therefor and the use thereof. The preparation method specifically comprises: taking an amorphous tefluthrin or a solid tefluthrin other than the tefluthrin as described in the present invention as a raw material, firstly preparing the raw material into an amorphous substance at room temperature, and then allowing the amorphous substance to cool to 5° C. to −24° C. to obtain a white or light yellow solid, i.e., a new crystalline form of tefluthrin.

Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

The present invention provides an industrially advantageous production method of (1R,2S)-2-{[((2,4-dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide.

(1R,2S)-2-{[((2,4-Dimethylpyrimidin-5-yl)oxyl}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (compound [A]) is produced by an industrially advantageous method by a route via a novel compound.

##STR00001##

wherein each symbol is as described in the description.

The present invention provides an industrially advantageous production method of (1R,2S)-2-{[((2,4-dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide.

(1R,2S)-2-{[((2,4-Dimethylpyrimidin-5-yl)oxyl}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (compound [A]) is produced by an industrially advantageous method by a route via a novel compound.

##STR00001##

wherein each symbol is as described in the description.

Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containg the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

The present invention belongs to the technical field of fine chemicals and relates to a new crystalline form of tefluthrin, a preparation method therefor and the use thereof. The preparation method specifically comprises: taking an amorphous tefluthrin or a solid tefluthrin other than the tefluthrin as described in the present invention as a raw material, firstly preparing the raw material into an amorphous substance at room temperature, and then allowing the amorphous substance to cool to 5° C. to −24° C. to obtain a white or light yellow solid, i.e., a new crystalline form of tefluthrin.